baber/WOPTO huggingface dataset:
Patent JP-2001524116-A (JP)
Title: ５ｈｔ１ａ、５ｈｔ１ｂおよび５ｈｔ１ｄ受容体アンタゴニスト活性を合わせ持つインドール誘導体
IPC: C07D403/12
Filed: 1998-04-14
Abstract: (57)【要約】
式（Ｉ）：
 ［式中、Ｒ a は式（ｉ）：
 （式中、Ｐ 1 はフェニル、二環式アリール、酸素、窒素およびイオウから選択される１ないし３個の異種原子を含む５ないし７員の複素環、または酸素、窒素およびイオウから選択される１ないし３個の異種原子を含む二環式複素環であり；Ｒ 1 は水素、ハロゲン、Ｃ 1-6 アルキル、Ｃ 3-6 シクロアルキル、ＣＯＣ 1-6 アルキル、Ｃ 1-6 アルコキシ、ヒドロキシ、ヒドロキシＣ 1-6 アルキル、ヒドロキシＣ 1-6 アルコキシ、Ｃ 1-6 アルコキシＣ 1-6 アルコキシ、Ｃ 1-6 アルカノイル、ニトロ、トリフルオロメチル、シアノ、ＳＲ 9 、ＳＯＲ 9 、ＳＯ 2 Ｒ 9 、ＳＯ 2 ＮＲ 10 Ｒ 11 、ＣＯ 2 Ｒ 10 、ＣＯＮＲ 10 Ｒ 11 、ＣＯ 2 ＮＲ 10 Ｒ 11 、ＣＯＮＲ 10 (ＣＨ 2 ) c ＣＯ 2 Ｒ 11 、(ＣＨ 2 ) c ＮＲ 10 Ｒ 11 、(ＣＨ 2 ) c ＣＯＮＲ 10 Ｒ 11 、(ＣＨ 2 ) c ＮＲ 10 ＣＯＲ 11 、(ＣＨ 2 ) c ＣＯ 2 Ｃ 1-6 アルキル、ＣＯ 2 (ＣＨ 2 ) c ＯＲ 10 、ＮＲ 10 Ｒ 11 、ＮＲ 10 ＣＯ 2 Ｒ 11 、ＮＲ 10 ＣＯＮＲ 10 Ｒ 11 、ＣＲ 10 ＝ＮＯＲ 11 、ＮＲ 10 ＣＯＯＲ 11 、ＣＮＲ 10 ＝ＮＯＲ 11 であり、ここにＲ 9 、Ｒ 10 およびＲ 11 は独立して水素またはＣ 1-6 アルキルであり、ｃは１ないし４であり；Ｒ 2 は水素、ハロゲン、Ｃ 1-6 アルキル、Ｃ 3-6 シクロアルキル、Ｃ 3-6 シクロアルケニル、Ｃ 1-6 アルコキシ、Ｃ 1-6 アルカノイル、アリール、アシルオキシ、ヒドロキシ、ニトロ、トリフルオロメチル、シアノ、ＣＯ 2 Ｒ 10 、ＣＯＮＲ 10 Ｒ 11 、ＮＲ 10 Ｒ 11 であり、ここにＲ 10 およびＲ 11 はＲ 1 に関する定義と同じであり；ａは１、２または３である）で示される基であるか、あるいはＲ a は式（ｉｉ）：
 （式中、Ｐ 2 およびＰ 3 は独立してフェニル、二環式アリール、酸素、窒素およびイオウか選択される１ないし３個の異種原子を含む５ないし７員の複素環、または酸素、窒素およびイオウから選択される１ないし３個の異種原子を含む二環式複素環基であり；Ａは結合または酸素、Ｓ（Ｏ） m （ｍは０ないし２）、カルボニル、ＣＨ 2 、−ＣＨ 2 −ＣＨ 2 −、またはＮＲ 4 であり、ここにＲ 4 は水素またはＣ 1-6 アルキルであり；Ｒ 1 は上記の式（ｉ）に関する定義と同じであるか、あるいはＲ 1 は、酸素、窒素またはイオウから選択される１ないし３個の異種原子を含み、Ｃ 1-6 アルキル、ハロゲンまたはＣ 1-6 アルカノイルにより置換されていてもよい、５ないし７員の複素環であり；Ｒ 2 およびＲ 3 は独立して水素、ハロゲン、Ｃ 1-6 アルキル、Ｃ 3-6 シクロアルキル、Ｃ 3-6 シクロアルケニル、Ｃ 1-6 アルコキシ、Ｃ 1-6 アルカノイル、アリール、アシルオキシ、ヒドロキシ、ニトロ、トリフルオロメチル、シアノ、ＣＯ 2 Ｒ 10 、ＣＯＮＲ 10 Ｒ 11 、ＮＲ 10 Ｒ 11 であり、ここにＲ 10 およびＲ 11 はＲ 1 に関する定義と同じであり；ａおよびｂは独立して０、１、２または３である）で示される基であり；Ｙは−ＮＨ−、−ＮＲ 5 −（ここにＲ 5 はＣ 1-6 アルキル）であるか、あるいはＹは−ＣＨ 2 −または−Ｏ−であり；Ｖは酸素またはイオウであり；Ｄは窒素、炭素またはＣＨ基であり；Ｗは(ＣＲ 16 Ｒ 17 ) t であり、ｔは２、３または４であり、Ｒ 16 およびＲ 17 は独立して水素またはＣ 1-6 アルキルであるか、あるいはＷは（ＣＲ 16 Ｒ 17 ) u −Ｊであり、ｕは０、１、２または３であり、Ｊは酸素、イオウ、ＣＲ 16 ＝ＣＲ 17 、ＣＲ 16 ＝Ｎ、＝ＣＲ 16 Ｏ、＝ＣＲ 16 Ｓまたは＝ＣＲ 16 −ＮＲ 17 であり；Ｘは窒素または炭素であり；Ｒ b は水素、ハロゲン、ヒドロキシ、Ｃ 1-6 アルキル、トリフルオロメチル、Ｃ 1-6 アルコキシ、Ｃ 2-6 アルケニル、Ｃ 1-4 アルキルにより置換されていてもよいＣ 3-7 シクロアルキル、またはアリールであり；Ｒ c は水素またはＣ 1-6 アルキルであり；
 は、Ｘが窒素である場合には一重結合であり、Ｘが炭素である場合には一重結合または二重結合である］で示される化合物、それらの製造方法ならびにＣＮＳ治療薬としてのそれらの使用を開示する。
Patent JP-2001523311-A (JP)
IPC: D21D5/00
Filed: 1998-05-04
Abstract: A method and apparatus for controlling a multi-step screening apparatus (1) controls other accept, reject and dilution flows in relation to the flow measured in the accept channel (7a) of the first screening step (3a). Thus a simpler control unit (9) can be used and accept of higher quality can be obtained than before. The apparatus has a control unit (9) aranged to measure the flows of all accept, reject and dilution water channels (7a-7c, 5a, 5b, 11a, 11b) and to adjust the flow of the other channels on the basis of the flow of the accept channel of the first step.
Patent JP-2002503410-A (JP)
Title: プログラム可能な工業用制御システムのための分散型インターフェイスアーキテクチャ
IPC: G05B19/042
Filed: 1998-05-06
Abstract: (57)【要約】
制御機能を実行すると共に該制御機能に関連するデータを（通常はセンサ又はビデオカメラから）収集するよう各々構成された１つ又は２つ以上のコントローラを備えた統合型制御システム。各コントローラは、前記関連するデータ及び該データに付随する（前記データを含む視覚的な表示を所定形式でリモートコンピュータに生成させる）命令を記憶するためのコンピュータメモリ等のコンピュータ記憶手段と、接続を確立すると共に前記リモートコンピュータとのデータ交換を容易にする通信モジュールとを備えている。該リモートコンピュータもまた、コントローラ側モジュールとの互換性を有し、リモートコンピュータによる前記データ（現在のビデオ情報及び／又は履歴及び／又は基準ビデオ情報及び１つ又は２つ以上のコントローラからの関連する命令を含む）のダウンロードを可能にする、通信モジュールを備えている。該リモートコンピュータはまた、前記命令を処理して該命令によりエンコードされ前記データを包含するユーザインターフェイスを生成する手段を備えている。このようにして、コントローラのデータが命令と結合されて該データの表示が行われ、かかる情報の全てが、リモートコンピュータに対して自由に選択可能な状態で連続的にアクセス可能なものとなる。
Patent MX-150823-A (MX)
Inventor: EUBANKS JERRY D
IPC: B65D43/24
Filed: 1980-05-29
Abstract: A stay for controlling the extent of opening and the rate of closing a case is disclosed which is intended to be less prone to damaging the contents of the case and accidental injury to fingers of the user. 
<??>A first version includes a flat, plate-like member (14) or resilient synthetic plastic having one end (15) pivotally connected to a stud (24) affixed to the inner end wall surface of one luggage shell (12). One of a pair of elongate, parallel curved slots (19 and 20) formed in the plate (14) is received onto a second stud (27) affixed to the other luggage part (11) such that when the two luggage parts are opened or closed on each other, the stud (27) will slide along and be guided by the slot (19). The second stud (27) has cross-sectional dimensions larger than the width of the slot (19) which distends the plastic material (22) between the two slots (19 and 20) producing a resilient clamping action on the stud (27). 
<??>A second version includes a metal plate (32) with an end (33) pivotally connected to a stud (42) on the inner surface of one shell (12 min ). A slot (37) in the plate (32) is received onto a stud (43) on the other luggage shell (11 min ) such that the stud will slide along and be guided by the slot (37). A thickened ear (40) is located immediately adjacent the slot (37) as a stop. A spring (48) and washer (47) on the stud (43) exert transverse pressure on the plate (32) as the stud (43) moves along the slot (37) deterring any tendency for the case parts to slam together.
Patent NZ-182682-A (NZ)
Title: Separating iron compounds from protein in blood substance-containing liquid
IPC: A23K10/24
Filed: 1976-11-22
Abstract: 1532848 Purifying proteins P G S LINDROOS 19 Nov 1976 [11 Dec 1975] 48376/76 Heading C3H  A method for separating iron compounds from the protein in a hemoglobin solution, comprises adding to said solution an organic solvent comprising ethanol in an amount such that the total ethanol content in the solution is at least 40% by volume, adjusting the pH of the liquid to a value lower than 4À5, whereby iron compounds in the solution are agglomerated, and thereafter separating the agglomerated iron compounds from the solution. The solution may be adjusted to a pH value which is less than 4À5 but greater than 2À5. Preferably the pH-value of the solution after agglomeration of the iron compounds is, before or after their separation, raised and wherein any fraction of blood protein precipitated thereby, with iron compounds included therein or adsorbed thereonto, is separated from the mixture. Before or after the agglomeration of iron compounds a minor quantity of broth of blood cells may be added to the solution and any flaky material of fragments of cell membrane formed thereby, together with iron compounds adsorbed thereonto, is then separated from the mixture. The organic solvent preferably includes a minor proportion of glycerin or ethylene glycol or methanol or acetone or ethylacetate or propanol or isopropanol or butanol. The iron compounds may be separated from the solution by centrifuging or a cyclone process or filtering or ultrafiltering or sedimenting or adsorption on to  voluminous or solid material, and the protein may be recovered from the solution by precipitation or adsorption on to solid or voluminous material or ultrafiltering or evaporation of the solution or drying or concentration of the solution by means of freezing.  The ethanol content in the solution after the agglomeration of iron compounds may be increased before or after their isolation and the fraction of blood protein precipitated thereby, together with any iron compounds included therein or adsorbed thereonto, may then be separated from the mixture. Before addition of ethanol to the solution and lowering of the pH of the solution, the solution is preferably cooled to a temperature of between zero and -20‹ C. and wherein this temperature is maintained during the entire further treatment.
Patent NZ-201210-A (NZ)
Title: Cleaning composition and aluminosilicate builders
Inventor: FOSTER F G
IPC: C11D3/12
Filed: 1982-07-09
Abstract: A low phosphate, alumino-silicate built cleaning composition having improved bleach performance is described comprising a) 15-50% by weight of a water-insoluble alumino-silicate cation exchange material;  b) 3-30% by weight of a peroxide bleach;  c) 0.5-15% by weight of an activator for said peroxide bleach; and d) 1-15% by weight of a nitrilotriacetic acid compound, wherein the percentage quantities of (a) + 2(d) is between 30 and 55.
Patent NZ-201588-A (NZ)
Title: 7-fluorinated derivatives of 3,6-diamino-n-hept-1-ene and-n-hept-1-yne
Inventor: CASARA P
IPC: C07F7/08
Filed: 1982-08-16
Abstract: Novel fluorinated diamino-heptene and-heptyne derivatives are inhibitors of ornithine decarboxylase enzyme and have the following general Formula I:- <CHEM>  wherein:-  Y represents CH2=CN- or CH IDENTICAL C-; and p represents 1 or 2. h
Patent NZ-206660-A (NZ)
Title: Cephem derivatives and pharmaceutical compositions
Inventor: DUCKHEIMER W
IPC: C07D501/46
Filed: 1983-12-21
Abstract: 1. Claims (for the Contracting States : BE, CH, DE, FR, GB, IT, LU, LI, NL, SE) A cephem derivative of the formula I  see diagramm : EP0111934,P10,F3  and physiologically acceptable acid addition salts thereof in which R**1 denotes C1 -C2 -alkyl, R**2 denotes a pyridinium radical  see diagramm : EP0111934,P10,F4  which is substituted by 2 alkyl groups in the ortho-position which are linked to form a trimethylene to pentamethylene ring in which one carbon atom can be replaced by an oxygen atom, or denotes a 1-quinolinium radical or a 2-isoquinolinium radical and in which the R**1 O group is in the syn-position. 1. Claims (for the Contracting State AT) A process for the preparation of a cephem derivative of the formula I see diagramm : EP0111934,P11,F4  and physiologically acceptable acid addition salts thereof in which R**1 denotes C1 -C2 -alkyl, R**2 denotes a pyridinium radical  see diagramm : EP0111934,P12,F1  which is substituted by 2 alkyl groups in the ortho-position which are linked to form a trimethylene to pentamethylene ring in which one carbon atom can be replaced by an oxygen atom, or denotes a 1-quinolinium radical or a 2-isoquinolinium radical in which the R**1 O group is in the syn-position which comprises a) reacting a compound of the general formula II  see diagramm : EP0111934,P12,F2  or salts thereof or a reactive derivative of the compound II in which R**1 has the meaning mentioned above and R**7 denotes an amino group or a protected amino group and R**8 denotes a group which can be replaced by the pyridine, quinoline or isoquinoline derivatives corresponding to the radicals R**2 of the formula I, with these pyridine, quinoline or isoquinoline derivatives, and alpha) splitting off a protective group which may be present and beta) if necessary, converting the resulting product into a physiologically acceptable acid addition salt, or b) reacting a 7-aminocephem compound of the general formula III  see diagramm : EP0111934,P12,F3  or acid addition salts thereof in which R**2 has the abovementioned meaning and in which the amino group can also be present in the form of a reactive derivative, with a 2-(5-amino-1,2,4-thiadiazol-3-yl)-2-synoximinoacetic acid of the general formula IV  see diagramm : EP0111934,P12,F4  in which R**1 and R**7 have the meaning mentioned above, or with an activated derivative of this compound, and alpha) splitting off a protective group which may be present, and beta) if necessary, converting the resulting product into a physiologically acceptable acid addition salt.
Patent NZ-211386-A (NZ)
Title: Purification,cloning and characterisation of the gene for interlukin 1beta
Inventor: CERRETTI D P
IPC: C12N1/19
Filed: 1985-03-11
Abstract: (1)Interleukin 1 (I), as a homogenous protein of molecular wt. about 17500 daltons and having a partial amino acid sequence of formula (II), is new. (2)Homogeneous human interleukin 1 consisting of a single protein species of molecular wt. of about 17500 daltons and having the following amino acid compsn. is new. The compsn. (amino acid and no. of residues/molecule, consists of Asp/Asn 14; Thr 8; Ser 11; Glu/Gln 22; Pro 6; Gly 11; Ala 8; Cys at least 1; Val 11; Met 4; Ile 6; Leu 11; Tyr 4; Phe 11; His 3; Lys 13; Arg 3. (3) Pure DNA encoding for the expression of human (I) molecules is new. (4) Recombinant DNA cloning vector comprising a CDNA sequence comprising the gene for (I) is new. (5)Recombinant DNA cloning vector comprising DNA as claimed in paragraph (3) above is new. (6)Host transformed by a cloning vector as defined in paragraphs (4) and (5) above is new.
Patent NZ-230716-A (NZ)
Title: Timer ticket with visibly indicating elapsed time: porous wick permeated by released liquid
Inventor: TOTHILL THOMAS WEBB
IPC: G04F13/06
Filed: 1989-09-20
Abstract: A timer comprising a lamination containing a piece of porous wick material (1), and a reservoir of liquid (6), said liquid (6) and/or said porous wick (1) being such that when the reservoir is opened and the liquid (6) released it soaks into the porous wick (1) to thereby create a visible trace of the liquid on or in the porous wick; a face part (2) of the lamination being transparent such that said visible trace can be seen; said wick material (1) having imposed thereon or positioned adjacent thereto a series of markings which cover the time range over which the timer is to be used. The invention also provides a method of manufacturing the timer.
Patent NZ-235727-A (NZ)
Title: Substituted oxazoles, preparation and pharmaceutical compositions thereof
Inventor: JARREAU FRANCOIS-XAVIER
IPC: A61P25/20
Filed: 1990-10-17
Abstract: The derivatives of the formula:   <IMAGE> (I)  wherein: R1 is H or C1-C4 alkyl; X is an oxygen atom, a methylene group or a -CH=CH- group; n is 1 or 2 when X is an oxygen atom or a methylene group and is 0 or 1 when X is a -CH=CH- group; R3 is a C1-C4 alkyl, C3-C7 cycloalkyl, phenyl, benzyl, CHF2, CF3 or CF3CF2 group; each of R2 and R'2 independently is a hydrogen atom or a C1-C4 alkyl, C4-C7 cycloalkyl, phenyl or benzyl group; R'2 and R3 may further form together a -(CH2)3- or -(CH2)4- chain; and each of R4 and R'4 independently is a C1-C4 alkyl group or R4 and R'4 form together either a -(CH2)2- or -(CH2)3- chain, a -(CH2)2- or -(CH2)3- chain substituted by one or two C1-C4 alkyl groups, or a -(CH2)2- chain substituted by one or two -CH2-NH2 groups or by one or two -CH2-NH2 groups N-substituted by one or two C1-C4 alkyl groups, useful as drugs.
Patent NZ-241140-A (NZ)
Title: Pharmaceutical compositions comprising condensed dihydropyridines and tautomers, and selected compounds
Inventor: LOSEL WALTER
IPC: A61K31/535
Filed: 1991-12-23
Abstract: 3,4-Dihydro-6,7-dimethoxy -1-(alpha-(bis(2-(2,3,4- trimethoxyphenyl)ethyl) -carbamoyl)benzyl)isoquinoline of formula (Ia) and its salts are new. Fused-ring dihydropyridine derivs. of formula (II) and their tautomers, salts and complexes are used as cerebroprotective agents, agents for treating chronic inflammatory disorders, and anticoagulants: X = OR1, NHR2 or NR3R4; R1 = H, 1-4C alkyl or 2-4C alkoxyalkyl; R2 = (a) e.g. H, 3-6C alkenyl, or (b) e.g. 1-6C alkyl opt. substd. by e.g. halogen, CN, OH, SH, 1-4C alkoxy; R3 and R4 = 1-4C alkyl opt. substd. by Ar2 or NR3R4 is a satd. or partially satd. opt. substd. 5- or 6-membered ring, opt. contg. up to two further heteroatoms (N, O and/or S): Ar1, Ar2 and R5 = phenyl opt. substd. by e.g. halogen, 1-4C alkoxy; Het = indolyl or 5- or 6-membered opt. substd. heterocyclyl contg. 1-3 heteroatoms (N, O and/or S); A = a gp. of formula A1-A4;: R5 is e.g. H, 1-4C alkyl; R6 and R7 is H, OH or R6+R7 = O(CH2)nO; R9 = H or 1-4C alkyl; R10 = H or 2-phenyl-2-ethoxycarbonylacetyl. Cpds. (I), other than (Ia), are described in EP 37934 and 251194.
Patent NZ-244295-A (NZ)
Title: Preparation of an isomer of cefepime from a silylated derivative
Inventor: LIM GARY F M
IPC: A61P31/04
Filed: 1992-09-10
Abstract: The present invention provides an anhydrous acylation process for the preparation of antibiotic, cefepime dihydrochloride hydrate which is substantially free of the anti-isomer and the  DELTA <2> isomer comprising the N-acylation of a silylated derivative of 7-amino-3-[(1-methyl-1-pyrrolidinio)-methyl]ceph-3-em-4-carboxylate with the syn-isomer of 2-(2-aminothiazol-4-yl)-2-methoxyimino acetyl chloride hydrochloride.
Patent NZ-266455-A (NZ)
Title: Forming a concrete tile with reinforcing ribs: tile making machine has a packshaft, roller, slipper and compaction device
Inventor: OBEROI BHUSHAN KUMAR
IPC: B28B1/29
Filed: 1994-04-28
Abstract: PCT No. PCT/EP94/01443 Sec. 371 Date Dec. 19, 1995 Sec. 102(e) Date Dec. 19, 1995 PCT Filed Apr. 28, 1994 PCT Pub. No. WO94/25235 PCT Pub. Date Nov. 10, 1994A roof tile making machine and its method of operation. The reinforcement ribs on the underside of a concrete roofing tile are formed during their manufacture by directing mortar into recesses in a pallet on which the tile is made, with a compactor means in the form of multi-tined wheels compacting the mortar in the recesses, and providing thereafter a secondary layer of mortar over the compacted reinforcement ribs, to complete the tile in a conventional manner. A tile provided by the apparatus of the invention has reinforcement ribs which are compacted to the same degree as the remainder of the tile, thereby ensuring that the finished product, when cured, has a uniform, or substantially uniform, strength.
Patent NZ-270812-A (NZ)
Title: Incinerator for medical waste; comprises a main combustion chamber and a recombustion chamber, details regarding the recombustion stage
Inventor: FUJIMORI MINORU
IPC: F23G5/40
Filed: 1995-03-27
Abstract: An incinerator (2) suitable for incineration of medical wastes is disclosed. The incinerator includes a main combustion chamber (4) with fire-resistant walls, a port (7) for ventin combustion gas therefrom and a main burner (3) in the front section of the chamber. A recombustion chamber (6) is placed above the main combustion chamber and includes fire resistant walls and has a recombustion burner (5) in a rear section of the recombustion chamber and receives the combustion gas from the main chamber through the port. An exhaust chamber (13) vents pollution free combustion gas from the recombustion chamber to the atmosphere. The port for introducing the combustion gas of the main combustion chamber to the recombustion chamber is positioned such that the port is spaced apart from the center of a flame of the recombustion burner to enable the combustion gas introduced into the recombustion chamber come into cross contact with the flame of the recombustion burner. <IMAGE>
Patent NZ-271797-A (NZ)
Title: Transdermal drug delivery patch having a basal matrix layer comprising a copolymer of 2-ethylhexyl acrylate and vinyl acetate, acrylic acid or methyl acrylate
Inventor: ROOS ERIC J
IPC: A61K31/565
Filed: 1994-08-05
Abstract: Matrix-type transdermal drug delivery devices for administering potent steroids such as ethinyl estradiol at a low flux steady-state rate over a multi-day period comprising a laminate of: (a) an occlusive backing layer and (b) a matrix layer of the drug completely dissolved at a loading of below 0.5% by weight in a 2-ethylhexyl acrylate copolymer.
Patent NZ-278171-A (NZ)
Title: Cylinder lock and key; key has profiled groove and cylinder plug has corresponding tongue
Inventor: WIDEN BO
IPC: E05B27/10
Filed: 1994-12-21
Abstract: A cylinder lock and key combination, where the key (20) has an undercut profile groove (24) at one side surface (22) thereof and, in the key slot (13), the lock key plug has a corresponding profile tongue (15) with a downwardly projecting end portion (15a), which fills up the undercut portion (29) of the key profile groove (24) upon insertion of the key into the lock.
Patent NZ-319008-A (NZ)
Title: Combined slot machine and racing game
Inventor: SEELIG MAC R
IPC: A63F9/14
Filed: 1996-09-19
Abstract: This gaming system includes one or more slot machines (10) associated with a racing display (20) wherein the racing elements (22) are not racing against each other.  Rather, a clock (24) is included and each racing element is racing against the clock, independently of the other racing elements.  The racing display (20) may be built directly into the slot machine so that the slot player can easily see the progress of his horse (22) or other racing element.  Alternatively, a large racing display may be utilized that displays a plurality of horses or other racing elements but wherein each horse is racing against a different clock rather than against each other.  Even further, Win, Place and Show positions are located adjacent the finish line, and the slot player whose horse (22) reaches either of these positions is awarded a prize depending on the position reached before the clock (24) has timed out.
Patent NZ-330744-A (NZ)
Title: A long qt syndrome gene which encodes kvlqt1 and its association with mink
Inventor: KEATING MARK F
IPC: C12N5/10
Filed: 1996-12-20
Abstract: One aspect of the invention relates to the identification of the molecular basis of long QT syndrome. More specifically, the invention has identified that mutated KVLQT1 causes long QT syndrome. The analysis of this gene will provide an early diagnosis of subjects with long QT syndrome. The diagnostic methods comprise analyzing the nucleic acid sequence of the KVLQT1 gene of an individual to be tested and comparing them with the nucleic acid sequence of the native, non-variant gene. Alternatively, the amino acid sequence of KVLQT1 may be analyzed for mutations which cause long QT syndrome. Presymptomatic diagnosis of long QT syndrome will enable practitioners to treat this disorder using existing medical therapy. A second aspect of the invention relates to the realization that KVLQT1 coassembles with minK to form a cardiac potassium channel.; This allows one to assay for drugs which interact with this channel to identify new drugs which are useful for treating or preventing long QT.
Patent NZ-333002-A (NZ)
Title: Ultrasonic Doppler speed measurement
Inventor: TAKAI TAKUO
IPC: G01S7/534
Filed: 1998-11-25
Abstract: In an acoustic Doppler speed measuring apparatus, the acoustic signal based on a reference frequency Fo is transmitted toward the moving object 50, and receiver 21 detects acoustic signals reflected from the moving object.  The notch filter 25 selectively attenuates signal at the reference frequency Fo before the Doppler signal Fd is derived from the mixing 23 and bandpass filtering 24 of the received signal.  The speed-computing unit 30 computes the speed of the moving object based on the Doppler signal component Fd.  The signal processing may be performed digitally.
Patent NZ-336563-A (NZ)
Title: Expression element having the sequence CGGCAGGGTCTC
Inventor: RASMUSSEN PREBEN
IPC: C12N15/80
Filed: 1998-03-02
Abstract: The specification describes the use of the sequence CGGCAGGGTCTC, or a variant, homologue or fragment thereof, as a control element for activating transcription of a nucleotide sequence or nucleotide sequences from a promoter. Accordingly there is  provided a nucleic acid construct in which at least one heterologous copy of the element is operatively linked upstream or downstream of a promoter which is itself operatively linked to a nucleotide sequence.
Patent NZ-504326-A (NZ)
Title: A multi-wall sack with string tear means in the top
Inventor: CHALLIS LARRY THOMAS
IPC: B65D33/00
Filed: 1998-11-02
Abstract: A multiwalled sack (1) comprising a closed bottom end (2) and an open top end that, when closed, forms a closed top end with a cover sheet (22) that includes tearing means (24) which facilitates easy opening of the sack.
Patent NZ-506553-A (NZ)
Title: Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of hcv viral antigen in host tissue
Inventor: BUYSE MARIE-ANGE
IPC: C12N5/10
Filed: 1999-03-29
Abstract: Antibodies to two new epitopes on the HCV envelope proteins were identified which allow routine detection of native HCV envelope antigens, in tissue or cells derived from the host. The new epitopes are: the E1 region aa 307-326 and the N-terminal hyper variable region of E2 aa 395-415. Surprisingly, we characterized an antibody which reacts with various sequences of the hypervariabie domain of E2. Specific monoclonal antibodies directed against these epitopes and allowing routine detection of viral antigen are described.